Form 4: Summit Therapeutics Co-CEO Buys $6M in Company Stock

Summit Therapeutics Co-CEO Robert W. Duggan acquired over 338,000 shares of company common stock in open market purchases totaling approximately $6 million.

Summary

• Robert W. Duggan, Co-Chief Executive Officer, Director, and 10% owner of Summit Therapeutics Inc. (SMMT), reported recent acquisitions of common stock.
• On September 10, 2025, Duggan acquired 333,394 shares at a weighted average price of $17.68 per share, totaling approximately $5,894,700.
• On September 11, 2025, an additional 5,000 shares were acquired at $18.07 per share, totaling $90,350.
• These transactions were executed pursuant to a Rule 10b5-1(c) trading plan.
• Following these acquisitions, Duggan's direct beneficial ownership stands at 556,093,090 shares.
• Indirect holdings include 31,000 shares by his spouse, 10,199,776 shares by the Shaun Zanganeh Irrevocable Trust, 25,457,666 shares by the Mahkam Zanganeh Revocable Trust, and 50,000 shares by an immediate family member of his spouse. Duggan disclaims beneficial ownership of these indirect securities, except for pecuniary interest.

Sentiment

Score: 9

Explanation: The reported acquisition of over $5.9 million in Summit Therapeutics common stock by Co-CEO and 10% owner Robert W. Duggan is a highly positive indicator. This substantial personal investment, even if executed under a 10b5-1 plan, demonstrates strong insider conviction in the company's current valuation and future growth trajectory.

Positives

• A significant insider, the Co-CEO and 10% owner, made substantial open market purchases of company stock, signaling strong confidence in the company's current valuation and future prospects.
• The total value of the purchases exceeds $5.9 million, representing a material investment by a key executive.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-meditated investment strategy rather than a reaction to immediate, potentially non-public, news.

Negatives

• No specific negative information is present in the filing itself, as it reports an insider purchase.

Risks

• Future market conditions or company performance could still impact the value of these acquired shares.
• While insider buying is generally positive, it does not guarantee future stock performance.

Future Outlook

The recent significant stock purchases by Co-CEO Robert W. Duggan, executed under a 10b5-1 plan, signal a strong and sustained belief in Summit Therapeutics' long-term value and future performance. This insider confidence suggests a positive outlook from management.

Management Comments

• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Industry Context

Insider buying, especially by a Co-CEO and significant owner, is generally viewed very positively by the market as it signals management's belief in the company's future prospects. For biotechnology or pharmaceutical companies like Summit Therapeutics, such a signal can be particularly important given the inherent risks and long development cycles, providing a vote of confidence.

Comparison to Industry Standards

• Insider buying by a Co-CEO and 10% owner is a strong signal, often interpreted more favorably than purchases by non-executive directors or smaller shareholders.
• The use of a 10b5-1 plan for these transactions is standard practice for insiders to avoid accusations of trading on material non-public information, demonstrating adherence to corporate governance best practices.
• The substantial volume of shares acquired and the existing large holdings highlight a significant personal investment in the company's success, which is a strong positive indicator compared to executives with minimal personal holdings.

Related Party Transactions

• Open market purchases of common stock by Robert W. Duggan, who is the Co-CEO, Director, and 10% owner.
• Indirect beneficial ownership through his spouse, trusts where his spouse is a trustee, and an immediate family member of his spouse.

Stakeholder Impact

• Shareholders: Likely to view the significant insider purchases as a strong vote of confidence from management, potentially boosting investor sentiment and interest in the stock.
• Employees: May interpret the insider buying as a positive sign of the company's stability and future prospects.

Key Dates

Recommendation

The reported acquisition of over $5.9 million in Summit Therapeutics common stock by Robert W. Duggan, who serves as Co-CEO, Director, and a 10% owner, is a powerful indicator of insider confidence. Such a substantial personal investment, even if pre-arranged via a 10b5-1 plan, suggests a strong belief in the company's intrinsic value and future growth potential. For a seasoned investor, this level of insider buying from a highly informed individual typically warrants a "strong buy" recommendation, as it implies the stock is currently undervalued or poised for significant appreciation.

Keywords

Summit Therapeutics, SMMT, Insider Buying, Form 4, Robert W. Duggan, Stock Purchase, 10b5-1 Plan, Co-CEO, Director, 10% Owner, Equity Acquisition